Research Projects

RESTART. Resistance to Radioimmunotherapy in pancreatic cancer: multi-omic approach towards personalized medicine.

Dr. Juan Dubrot Armendariz
Researcher | Principal Investigator Tumor Evasion and Novel Targets Research Group

Project information

Resistance to Radioimmunotherapy (RESTART) in pancreatic cancer: a multi-omic approach towards personalized medicine.

The RESTART project seeks to study resistance to radioimmunotherapy in pancreatic cancer through a multi-omic approach that allows defining and developing the best therapeutic strategy for each patient, achieving personalized medicine.

  • Convocation: INVESTIGADOR AECC 2023
  • Duration: 3
  • Start date: September 1, 2023
  • End date: August 31, 2026
  • Funder: Asociación Española contra el Cáncer
  • Nature of project: National
  • Award year 2023

Need more information?

If you are interested in learning more about our research, please contact us.